Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives.
Burden of illness
Chronic kidney disease
Cost-of-illness
Health costs
Hemodialysis
Kidney transplantation
Peritoneal dialysis
Pharmacoeconomics
Societal perspective
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
01 May 2022
01 May 2022
Historique:
received:
16
09
2021
accepted:
11
04
2022
entrez:
3
5
2022
pubmed:
4
5
2022
medline:
6
5
2022
Statut:
epublish
Résumé
Chronic kidney disease (CKD) is the 12 This is a cross-sectional study of CKD patients who presented to two nephrology clinics during November 2020. Their medical and administrative records were reviewed for collection of demographics, CKD characteristics, direct medical costs (medications, diagnostic tests, hospitalizations, inpatient care, outpatient care), direct non-medical costs (transportation) and indirect costs (productivity losses) for one year. Kruskal Wallis test was used to compare the costs between different CKD stages and categories. Logistic regression analysis was used to evaluate risk factors associated with costs. The sample included 102 non-dialysis CKD patients, 40 hemodialysis, 8 peritoneal dialysis and 10 transplant patients. Their mean age was 66.74 ± 15.36 years, 57.5% were males and 42.5% diabetics. The total median cost per year of CKD across all categories was assessed to be 7,217,500 Lebanese Pounds (3,750,000-35,535,250; 1 $USD = 1515 LBP in 2019) from the societal perspective and 5,685,500 LBP (2,281,750- 32,386,500) from the third-party payer perspective. Statistical analysis showed a higher total cost in hemodialysis (p < 0.001), higher cost of medications in transplant (p < 0.001) and higher cost in technique modality in peritoneal dialysis (p < 0.001). In a sub-analysis of hemodialysis patients, dialysis vintage negatively correlated with total societal cost (r = -0.391, p = 0.013); the regression analysis found diabetes as a risk factor for higher cost (OR = 2.3; 95%CI: 0.638,8.538; p = 0.201). In the subcategory of CKD-ND patients, age correlated with total societal cost (r = 0.323, p = 0.001); diabetes and coronary artery disease were significantly associated with higher total cost (OR = 2.4; 95%CI: 1.083,5.396; p = 0.031; OR = 3.7; 95%CI: 1.535,8.938; p = 0.004). This cost of illness study showed a high burden of hemodialysis and peritoneal dialysis cost compared to transplant and non-dialysis CKD patients. It revealed a significantly higher cost of medications in transplant patients. Health policies should target interventions that prevent end-stage kidney disease and encourage kidney transplantation.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic kidney disease (CKD) is the 12
METHODS
METHODS
This is a cross-sectional study of CKD patients who presented to two nephrology clinics during November 2020. Their medical and administrative records were reviewed for collection of demographics, CKD characteristics, direct medical costs (medications, diagnostic tests, hospitalizations, inpatient care, outpatient care), direct non-medical costs (transportation) and indirect costs (productivity losses) for one year. Kruskal Wallis test was used to compare the costs between different CKD stages and categories. Logistic regression analysis was used to evaluate risk factors associated with costs.
RESULTS
RESULTS
The sample included 102 non-dialysis CKD patients, 40 hemodialysis, 8 peritoneal dialysis and 10 transplant patients. Their mean age was 66.74 ± 15.36 years, 57.5% were males and 42.5% diabetics. The total median cost per year of CKD across all categories was assessed to be 7,217,500 Lebanese Pounds (3,750,000-35,535,250; 1 $USD = 1515 LBP in 2019) from the societal perspective and 5,685,500 LBP (2,281,750- 32,386,500) from the third-party payer perspective. Statistical analysis showed a higher total cost in hemodialysis (p < 0.001), higher cost of medications in transplant (p < 0.001) and higher cost in technique modality in peritoneal dialysis (p < 0.001). In a sub-analysis of hemodialysis patients, dialysis vintage negatively correlated with total societal cost (r = -0.391, p = 0.013); the regression analysis found diabetes as a risk factor for higher cost (OR = 2.3; 95%CI: 0.638,8.538; p = 0.201). In the subcategory of CKD-ND patients, age correlated with total societal cost (r = 0.323, p = 0.001); diabetes and coronary artery disease were significantly associated with higher total cost (OR = 2.4; 95%CI: 1.083,5.396; p = 0.031; OR = 3.7; 95%CI: 1.535,8.938; p = 0.004).
CONCLUSIONS
CONCLUSIONS
This cost of illness study showed a high burden of hemodialysis and peritoneal dialysis cost compared to transplant and non-dialysis CKD patients. It revealed a significantly higher cost of medications in transplant patients. Health policies should target interventions that prevent end-stage kidney disease and encourage kidney transplantation.
Identifiants
pubmed: 35501814
doi: 10.1186/s12913-022-07936-0
pii: 10.1186/s12913-022-07936-0
pmc: PMC9063193
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
586Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
J Med Econ. 2016 Oct;19(10):1018-9
pubmed: 27494379
BMJ Open. 2020 Sep 30;10(9):e036317
pubmed: 32998917
Clin Nephrol. 2020 Supplement Jan;93(1):17-20
pubmed: 32145758
BMC Health Serv Res. 2020 Feb 18;20(1):126
pubmed: 32070341
BMC Health Serv Res. 2015 Nov 12;15:506
pubmed: 26563300
Clin Nephrol. 2020 Supplement Jan;93(1):120-123
pubmed: 31793874
Nephrol Dial Transplant. 2008 Jul;23(7):2365-73
pubmed: 18234844
Hemodial Int. 2017 Oct;21(4):445-452
pubmed: 27966247
Can J Kidney Health Dis. 2021 Jun 04;8:20543581211018528
pubmed: 34158964
Nephrol Dial Transplant. 2013 Oct;28(10):2553-69
pubmed: 23737482
East Mediterr Health J. 2019 Mar 19;25(2):134-141
pubmed: 30942478
PLoS One. 2020 Mar 24;15(3):e0230512
pubmed: 32208435
J Med Econ. 2016 Dec;19(12):1157-1166
pubmed: 27352200
Bull World Health Organ. 2018 Jun 1;96(6):414-422D
pubmed: 29904224
Int J Equity Health. 2020 Jun 8;19(1):90
pubmed: 32513177
Rev Assoc Med Bras (1992). 2018 Dec;64(12):1108-1116
pubmed: 30569987
Clin Transplant. 2021 Sep;35(9):e14372
pubmed: 34033140
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
PLoS One. 2020 Apr 24;15(4):e0231375
pubmed: 32330140
Eur J Health Econ. 2017 Sep;18(7):847-858
pubmed: 27699568
Clin Nephrol. 2020 Supplement Jan;93(1):100-102
pubmed: 31397268
Clin Mol Hepatol. 2014 Dec;20(4):327-37
pubmed: 25548737
BMJ Open. 2021 Jul 9;11(7):e047245
pubmed: 34244267
J Am Soc Nephrol. 2020 Jul;31(7):1594-1601
pubmed: 32487562
BMC Health Serv Res. 2020 May 11;20(1):403
pubmed: 32393380
Int J Environ Res Public Health. 2021 Apr 28;18(9):
pubmed: 33925259